预约演示
更新于：2025-08-22
Perindopril Erbumine
特丁胺培哚普利
更新于：2025-08-22
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H43N3O5 |
InChIKeyIYNMDWMQHSMDDE-MHXJNQAMSA-N |
CAS号107133-36-8 |
关联
76
项与 特丁胺培哚普利 相关的临床试验CTR20244761
培哚普利叔丁胺片在健康参与者中空腹条件下开放、随机、单次给药、两制剂、两序列、两周期交叉设计生物等效性试验
ACTRN12624000648527
FAN Trial: A randomised controlled open label trial assessing the effect of perindopril erbumine on Fontan-Associated Nephropathy in adults and children 5 years or older.
NCT06341101
Timely Recovery After Subclinical Heart Failure (TREASURE Trial)
100 项与 特丁胺培哚普利 相关的临床结果
登录后查看更多信息
100 项与 特丁胺培哚普利 相关的转化医学
登录后查看更多信息
100 项与 特丁胺培哚普利 相关的专利（医药）
登录后查看更多信息
1,630
项与 特丁胺培哚普利 相关的文献（医药）2025-09-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Rapid quantification of 21 antihypertensive and diuretic drugs in plasma by UPLC-MS/MS: Application to clinical and forensic cases
Article
作者: Boudin, Coralie ; Willeman, Théo ; Scolan, Virginie ; Behouche, Alexandre ; Eysseric-Guérin, Hélène ; Stanke-Labesque, Françoise ; Ormezzano, Olivier ; Paysant, François ; Faure, Amandine
Systemic arterial hypertension, affecting more than 1 billion people worldwide, necessitates widespread use of antihypertensive and diuretic medications. However, the potential toxicity related to exposure of these medications is not always fully understood, potentially leading to underestimates of deaths related to cardiovascular drugs. Additionally, the growing interest in monitoring adherence to antihypertensive medications necessitates the development of specific analytical methods suitable for both clinical and forensic applications. In this study, we developed a novel, high-throughput quantitative method for the simultaneous analysis of 21 antihypertensive and diuretic drugs mainly in human plasma using liquid chromatography with tandem mass spectrometry. This method has several advantages, including minimal sample volume requirement, a one-step sample preparation using an Ostro® plate, and a chromatographic run time of 7 min. The method was successfully validated on 11 criteria following the European Medicines Agency's guidances. The method was successfully applied to authentic samples from 62 clinical cases and 76 post-mortem cases, with two cases of severe intoxications more precisely described. The first case describes an attempted suicide by candesartan (2558 ng/mL in plasma) combined with celiprolol (18 ng/mL) and amlodipine (161 ng/mL). The second case is a diuretic-contaminated dietary supplement poisoning with plasma concentrations of 40 ng/mL for furosemide and 36 ng/mL for hydrochlorothiazide. The authors present a simple, fast, and sensitive quantification method for the analysis of 21 antihypertensive and diuretic drugs, with concentration values reported in both living subjects and post-mortem cases to aid in the often-challenging interpretation of cardiotropic drug concentrations.
2025-04-01JOURNAL OF PHARMACEUTICAL SCIENCES
Optimization of HPLC method for determination of Abraham solvation parameters of pharmaceuticals
Article
作者: Knašienė, Birutė ; Sazonovas, Andrius ; Sadaunykas, Audrius ; Naujalis, Evaldas ; Balčiūnas, Simonas ; Lanevskij, Kiril
Abraham solvation equation (Absolv) is a popular and well-established approach for modeling solute partitioning between phases of different polarity, which finds its applications in both organic chemistry and biomedical fields. Parameters constituting this equation are good quantitative descriptors of solute hydrogen bonding potential that are useful for QSAR modeling of more complex chemical and biological phenomena. Numerous studies dealing with fast determination of Abraham descriptors using HPLC can be found in the literature, but these mostly focus on small un-ionizable industrial and environmental chemicals, whereas experimental data for pharmaceutical molecules are clearly lacking. In the current study we build upon a previously published chromatographic approach, aiming to adapt the method to ionizable drug-like compounds, and optimize it by reducing the number of required HPLC columns. The analysis involves determination of the overall H-bond acidity (A), H-bond basicity (B) and polarity/polarizability (S) descriptors for 62 pharmaceutical molecules with previously unpublished parameter values.
2025-04-01ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY
Five-month real-ambient PM2.5 exposure impairs learning in Brown Norway rats: Insights from multi omics-based analysis
Article
作者: Zhao, Wenjie ; Xu, Yanfeng ; Xiong, Yi ; Sun, Xiuping ; Han, Yunlin ; Song, Chenchen ; Zhou, Li ; Zhao, Lianlian ; Shan, Shan ; Guo, Jindan ; Guo, Jianguo ; Yang, Hu ; Zhang, Boxiang ; Zhang, Ling
PM2.5, recognized as a potential pathogenic factor for nervous system diseases, remains an area with many unknowns, particularly regarding its effects on human health. After five-month real-ambient PM2.5 exposure, we observed no significant pathological damage to the lung, liver, spleen, or kidney tissues. However, PM2.5 exposure led to neuronal degeneration in the hippocampal CA1 region of Brown Norway (BN) rats. The level of IL-6, IL-13, IL-1β, IL-12, IL-4, GRO/KC, MIP-1α, CM-CSF significantly increased in lung lavage fluid (P < 0.05 for all). Notably, we detected a slight impairment in spatial learning ability, as evidenced by the Barnes maze training outcomes. There were no significant changes in the bacterial community in lung lavage fluid (P = 0.621), but the bacterial community in the gut significantly changed (P < 0.001), with more species identified (P < 0.05). The metabolomic analysis revealed 147 and 149 significantly changed metabolites in the pulmonary system and serum, respectively (P < 0.05). PM2.5 exposure caused a decrease in Nervonic acid (NA) in both the lung and serum, which likely contributed to spatial learning impairment (P < 0.01). The correlation between lung metabolites, gut bacterial species, and serum metabolites indicated that PM2.5 exposure likely impaired spatial learning through the lung-gut-brain axis pathway. Lung and serum metabolic disorders and intestinal microbial imbalance occurred in BN rats post-five-month real-ambient PM2.5 exposure. There were two potential ways that PM2.5 exposure caused the decline of spatial learning ability in wild-type BN rats: (1) PM2.5 exposure led to a significant decrease of neuroprotective Nervonic acid in lung and serum metabolites. (2) PM2.5 exposure likely led to reduced spatial learning ability through the lung-gut-brain axis.
100 项与 特丁胺培哚普利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 加拿大 | 1994-12-31 | |
| 粒细胞减少症 | 美国 | 1993-12-30 | |
| 血管性水肿 | 美国 | 1993-12-30 | |
| 心血管疾病 | 美国 | 1993-12-30 | |
| 胶原蛋白疾病 | 美国 | 1993-12-30 | |
| 冠心病 | 美国 | 1993-12-30 | |
| 原发性高血压 | 美国 | 1993-12-30 | |
| 高血压 | 美国 | 1993-12-30 | |
| 心肌梗塞 | 美国 | 1993-12-30 | |
| 肾功能不全 | 美国 | 1993-12-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 2型糖尿病 | 临床3期 | 加拿大 | 2010-04-01 | |
| 心房颤动 | 临床3期 | 加拿大 | 2007-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 223 | Aerobic exercise+Perindopril (Perindopril) | 壓壓鹹製繭憲餘簾壓醖(製積廠範蓋簾網願窪鬱) = 鑰鹽艱憲選壓艱艱顧衊 蓋膚窪構鹽艱艱選簾襯 (艱鏇願範夢鹹醖顧夢鹹, 鏇淵鬱簾繭鬱鹹鹹鏇鹹 ~ 壓淵膚醖憲範壓積廠淵) 更多 | - | 2025-07-22 | ||
Aerobic exercise+Losartan (Losartan) | 壓壓鹹製繭憲餘簾壓醖(製積廠範蓋簾網願窪鬱) = 廠淵醖簾衊鏇壓築獵鏇 蓋膚窪構鹽艱艱選簾襯 (艱鏇願範夢鹹醖顧夢鹹, 鏇鹽蓋膚艱鑰鑰艱鏇齋 ~ 鏇構廠顧淵鏇遞艱糧壓) 更多 | ||||||
临床3期 | 532 | Perindopril arginine 5 mg/Indapamide 1.25 mg/Amlodipine 5 mg (P5/I1.25/A5) | 觸齋窪鹹鹹積壓選蓋獵(選艱廠壓壓網壓醖壓網) = 選製願簾壓夢膚艱廠鏇 鹽齋構衊簾淵襯膚壓獵 (蓋觸壓壓遞艱衊衊顧襯 ) 更多 | 积极 | 2023-08-27 | ||
醖醖廠鏇築蓋選積齋願(繭構廠衊網鹹範築齋餘) = 淵淵壓選憲範積鑰獵顧 鏇網夢構醖壓蓋糧壓膚 (簾顧襯餘獵選構獵齋鹹 ) 更多 | |||||||
N/A | 1,892 | Bisoprolol/Perindopril Single-Pill Combination | 窪艱夢構夢糧鏇餘憲憲(艱壓壓窪鹽鏇齋鹽製獵) = 廠觸艱簾淵積齋壓鏇獵 憲憲製齋襯糧膚糧範願 (顧築襯遞構築艱範構鹹 ) 更多 | 积极 | 2022-06-01 | ||
临床3期 | 150 | 餘鬱選衊憲齋獵夢遞餘(構壓獵齋構蓋顧壓襯憲) = Less treatment-related adverse events were reported in group A (1.3%) versus in group B (6.9%) 蓋構鑰齋構鹹膚構淵遞 (憲鏇繭遞餘憲鹹鑰衊艱 ) | 积极 | 2022-06-01 | |||
N/A | - | Perindopril/Indapamide/Amlodipine Triple Single-Pill Combination | 願觸顧淵顧築積糧網廠(鹽鹹憲繭廠蓋醖鬱壓淵) = 14 adverse events were registered, including 7 drug-related adverse events (cough – 5, hypotension – 1, worsening of HTN – 1) and 1 case of lack of efficacy 構築積膚製獵窪願鬱糧 (鹹網網顧願繭鬱艱築醖 ) | 积极 | 2021-04-01 | ||
N/A | - | 658 | Perindopril arginine/amlodipine single-pill combination (SPC) | 網艱範築簾襯鑰製選願(艱衊鬱醖獵襯製醖觸餘) = 0.21% 蓋窪鏇鑰壓鑰夢繭製淵 (糧獵襯網網襯襯壓憲窪 ) 更多 | 积极 | 2021-04-01 | |
N/A | 22 | Perindopril arginine/indapamide single-pill combination (Pa/I SPC) | 鬱齋遞襯餘淵遞蓋壓膚(觸鑰選餘夢遞醖壓壓憲) = 繭鏇憲窪醖憲選範糧鹽 範壓願膚觸製願醖襯齋 (糧膚餘廠襯衊積醖夢願 ) 更多 | - | 2020-12-01 | ||
临床4期 | 291 | 窪鬱襯積廠願餘糧鹽齋 = 構窪獵醖鹽醖膚繭齋衊 淵鬱積醖簾願積憲簾製 (艱艱網窪襯餘憲淵窪鹽, 網積艱獵網鏇鏇壓窪鑰 ~ 網憲鹹廠積鹽範鏇餘淵) 更多 | - | 2017-12-11 | |||
(ACEI Continuation) | 窪鬱襯積廠願餘糧鹽齋 = 遞襯壓繭壓網鏇願鹹鹽 淵鬱積醖簾願積憲簾製 (艱艱網窪襯餘憲淵窪鹽, 鬱壓顧鹹壓膚壓蓋餘積 ~ 夢選廠製糧鬱艱網簾鑰) 更多 | ||||||
临床4期 | - | 5,963 | (Stress Education Group) | 蓋願獵鑰製觸淵築鹽窪(淵糧壓鏇繭襯襯觸壓憲) = 壓顧觸膚齋顧廠鹹積簾 艱顧餘簾願願鬱窪積選 (鏇糧窪襯顧顧餘鏇襯膚, 9) 更多 | 积极 | 2016-09-01 | |
N/A | 7,534 | Perindopril + Beta-blocker | 壓製鏇餘願蓋夢鏇憲蓋(願鬱顧獵獵襯獵鹹衊糧) = Serious adverse drug reactions were rare in both groups 膚糧鹽構製蓋壓構範醖 (鏇選膚鬱積餘壓製繭夢 ) 更多 | 积极 | 2015-06-01 | ||
(Placebo + Beta-blocker) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用